Fineline Cube

Follow:
14855 Articles
Xiangxue Pharma's XLS-103 Wins NMPA Clinical Trial Approval for KRAS G12V–Positive Advanced Colorectal Cancer – Proprietary TCR-T Cell Therapy Expands to Third Tumor Type in China
CompanyDrug

Xiangxue Pharma’s XLS-103 Wins NMPA Clinical Trial Approval for KRAS G12V–Positive Advanced Colorectal Cancer – Proprietary TCR-T Cell Therapy Expands to Third Tumor Type in China

Innovent's Sintilimab Plus Nogileucel (GC101) Melanoma NDA Accepted by NMPA – Backed by 57% Progression Risk Reduction in MIZAR-003
Others

Innovent’s Sintilimab Plus Nogileucel (GC101) Melanoma NDA Accepted by NMPA – Backed by 57% Progression Risk Reduction in MIZAR-003

WuXi AppTec Q3 Revenue Jumps 38% as Backlog Hits RMB 76.74 Billion – Full-Year Guidance Raised
Company

WuXi AppTec Q3 Revenue Jumps 38% as Backlog Hits RMB 76.74 Billion – Full-Year Guidance Raised

HutchMed's SANOVO Phase III Hits Primary Endpoint – ORPATHYS Plus TAGRISSO Extends Median PFS to 24.9 Months in MET-Overexpressing EGFR-Mutant NSCLC
CompanyDrug

HutchMed’s SANOVO Phase III Hits Primary Endpoint – ORPATHYS Plus TAGRISSO Extends Median PFS to 24.9 Months in MET-Overexpressing EGFR-Mutant NSCLC

Regeneron Extends BARDA Agreement With $270 Million Inmazeb Supply Deal for U.S. Ebola Preparedness Through 2031
CompanyDeals

Regeneron Extends BARDA Agreement With $270 Million Inmazeb Supply Deal for U.S. Ebola Preparedness Through 2031

Astellas' Non-Hormonal VEOZA Gains NMPA NDA Acceptance for Menopausal Hot Flashes in China
CompanyDrug

Astellas’ Non-Hormonal VEOZA Gains NMPA NDA Acceptance for Menopausal Hot Flashes in China

Sino Biopharmaceutical's CTTQ Earns Dual CDE Breakthrough Therapy Designations for TQ-A3334 and TQA3605 in Chronic Hepatitis B
CompanyDrug

Sino Biopharmaceutical’s CTTQ Earns Dual CDE Breakthrough Therapy Designations for TQ-A3334 and TQA3605 in Chronic Hepatitis B

FDA Expands Pfizer's TALZENNA-XTANDI Approval to Earlier-Line HRR-Mutated Metastatic Prostate Cancer
CompanyDrug

FDA Expands Pfizer’s TALZENNA-XTANDI Approval to Earlier-Line HRR-Mutated Metastatic Prostate Cancer

Hengrui Wins NMPA Trial Clearance for First-in-Class SHR-2005 Combination in Bladder Cancer
CompanyDrug

Hengrui Wins NMPA Trial Clearance for First-in-Class SHR-2005 Combination in Bladder Cancer

AstraZeneca's Imfinzi Combo Cuts Death Risk 42% in Phase III VOLGA Trial – Landmark Perioperative Win in Muscle-Invasive Bladder Cancer
CompanyDrug

AstraZeneca’s Imfinzi Combo Cuts Death Risk 42% in Phase III VOLGA Trial – Landmark Perioperative Win in Muscle-Invasive Bladder Cancer

InnoCare Pharma Q3 Revenue Surges 150.6% as Orelabrutinib Expansion Drives Turnaround to Profitability
Company

InnoCare Pharma Q3 Revenue Surges 150.6% as Orelabrutinib Expansion Drives Turnaround to Profitability

Novartis Raises Full-Year Core Profit Guidance as Q3 Sales Grow 4% – Kisqali Surges 37% to Lead Priority Brands
Company

Novartis Raises Full-Year Core Profit Guidance as Q3 Sales Grow 4% – Kisqali Surges 37% to Lead Priority Brands